Droia invests globally in young drug development companies that use novel science and innovative approaches to bring promising therapies to patients. We are specialists, investing exclusively in therapeutics for oncology and genetic disease.
Our focus and our in-house team of drug development experts and biotech professionals allow us to accelerate our companies’ progress by actively supporting them from company creation through clinical proof of concept. We are hands-on investors and entrepreneurs, fully dedicated to making an impact and saving patient lives.
For biotech companies, ultimate success is measured in effective patient benefit. Promising therapies should have a material impact on patient prognosis, measured as a function of the severity of the unmet medical need addressed and the improvement in therapeutic benefits as compared to (expected) standard of care.
We only invest in companies that are able, through their technology platforms or scientific insights, to go after previously unsolvable clinical problems. Companies should differentiate not only by way of innovation, but also in the way this innovation translates to clinical breakthrough.
Droia actively scouts for the best science and the best teams. Whether investing in an existing company or creating a new company, we actively participate in our portfolio companies’ development. Our team has deep and specialized experience in disease biology, translational science, clinical development and company building.
We have built many companies from the ground up, supporting and complementing founders and management teams. Our team members dedicate their time to helping their companies, and will take on interim roles within companies to help them get off the ground faster. Our whole organization is geared towards doing what we do best: building great drug development companies.
Droia Labs is the scientific arm of Droia Ventures and validates novel ideas for young drug development companies. Droia Labs provides state-of-the-art facilities to deliver cutting edge science on groundbreaking ideas. With our team of seasoned scientists and entrepreneurs we make our contribution to ultimately deliver life-changing medicines to patients in need.
* representing Wepaven BV
* representing Primix Bio Ventures BV
* representing MARA Consulting BV
* Representing KinCon BV
* representing Consillis BV
* representing ADP Ventures BV
* representing Lizalias BV
* Representing Moira Thread Management
VLS-1488 is a potent oral KIF18A inhibitor with the potential to be the first-ever chromosomal instability-targeted cancer therapy. Phase Ib trial for sovilnesib, Volastra’s second KIF18A inhibitor, is anticipated to open in Q1 2024....
HMBD-001 is Hummingbird Bioscience’s proprietary anti-HER3 antibody in Phase I/IIa trials in the UK and Phase Ib trials in Australia, targeting multiple solid tumors. The clinical data shows that HMBD-001 is safe and well-tolerated with no dose-limi...
Endeavor obtains exclusive worldwide rights to Hummingbird Bioscience’s anti-HER3 ADC to be developed for patients with HER3-expressing tumors. Hummingbird Bioscience to receive upfront and milestone payments up to $430 million, plus royalties, from...
Droia is currently recruiting for its investment and development team. The team scouts for new opportunities, evaluates companies and projects, manages the investment and exit process, and works with the portfolio companies on their progress.
Team members work closely with the portfolio companies at management or board level, and play a hands-on role in all aspects of the drug development process.
Droia is an entrepreneurial environment, where everyone is above all committed to making things happen.
Applicants should have relevant experience in biomedical science, drug development and/or life science investing.